(Reuters) -The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' lenacapavir, a twice-yearly injection ...

Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...

Gilead Sciences has received US FDA approval for Yeztugo, its bi-annual HIV prevention injection, which has shown 96 per cent ...

The FDA has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a pre-exposure prophylaxis (PrEP) against ...

The US Food and Drug Administration on Wednesday approved Gilead Sciences’ twice-yearly injection to prevent HIV - a move the ...

Gilead's CEO says he's committed to making sure people around the world can get his firm's new HIV prevention shot Yeztugo.

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move ...

Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD ...

Gilead Sciences, Inc., a biopharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) ...

The drug, known as Yeztugo, is the first and only twice-yearly option available in the U.S. for people who need or want PrEP, Gilead said Wednesday. Just under 100% of patients who received the drug ...

The launch of the injection faces potential threats, including the Trump administration’s proposed cuts to federal funding ...